BACKGROUND AND PURPOSE: Complex-shaped malignant pleural mesotheliomas (MPMs) with challenging volumes are extremely difficult to treat by conventional radiotherapy due to tolerance doses of the surrounding normal tissue. In a feasibility study, we evaluated if inversely planned stereotactic intensity-modulated radiation therapy (IMRT) could be applied in the treatment of MPM. PATIENTS AND METHODS: Eight patients with unresectable lesions were treated after failure of chemotherapy. All patients were positioned using noninvasive patient fixation techniques which can be attached to the applied extracranial stereotactic system. Due to craniocaudal extension of the tumor, it was necessary to develop a special software attached to the inverse planning program KonRad, which can connect two inverse treatment plans and consider the applied dose of the first treatment plan in the area of the matchline of the second treatment plan. RESULTS: Except for one patient, in whom radiotherapy was canceled due to abdominal metastasis, treatment could be completed in all patients and was well tolerated. Median survival after diagnosis was 20 months and after IMRT 6.5 months. Therefore, both the 1-year actuarial overall survival from the start of radiotherapy and the 2-year actuarial overall survival since diagnosis were 28%. IMRT did not result in clinically significant acute side effects. By using the described inverse planning software, over or underdosage in the region of the field matchline could be prevented. Pure treatment time ranged between 10 and 21 min. CONCLUSION: This study showed that IMRT is feasible in advanced unresectable MPM. The presented possibilities of stereotactic IMRT in the treatment of MPM will justify the evaluation of IMRT in early-stage pleural mesothelioma combined with chemotherapy in a study protocol, in order to improve the outcome of these patients. Furthermore, dose escalation should be possible by using IMRT.
BACKGROUND AND PURPOSE: Complex-shaped malignant pleural mesotheliomas (MPMs) with challenging volumes are extremely difficult to treat by conventional radiotherapy due to tolerance doses of the surrounding normal tissue. In a feasibility study, we evaluated if inversely planned stereotactic intensity-modulated radiation therapy (IMRT) could be applied in the treatment of MPM. PATIENTS AND METHODS: Eight patients with unresectable lesions were treated after failure of chemotherapy. All patients were positioned using noninvasive patient fixation techniques which can be attached to the applied extracranial stereotactic system. Due to craniocaudal extension of the tumor, it was necessary to develop a special software attached to the inverse planning program KonRad, which can connect two inverse treatment plans and consider the applied dose of the first treatment plan in the area of the matchline of the second treatment plan. RESULTS: Except for one patient, in whom radiotherapy was canceled due to abdominal metastasis, treatment could be completed in all patients and was well tolerated. Median survival after diagnosis was 20 months and after IMRT 6.5 months. Therefore, both the 1-year actuarial overall survival from the start of radiotherapy and the 2-year actuarial overall survival since diagnosis were 28%. IMRT did not result in clinically significant acute side effects. By using the described inverse planning software, over or underdosage in the region of the field matchline could be prevented. Pure treatment time ranged between 10 and 21 min. CONCLUSION: This study showed that IMRT is feasible in advanced unresectable MPM. The presented possibilities of stereotactic IMRT in the treatment of MPM will justify the evaluation of IMRT in early-stage pleural mesothelioma combined with chemotherapy in a study protocol, in order to improve the outcome of these patients. Furthermore, dose escalation should be possible by using IMRT.
Authors: S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz Journal: Strahlenther Onkol Date: 2012-02-10 Impact factor: 3.621
Authors: Falk Roeder; Carmen Timke; Felix Zwicker; Christian Thieke; Marc Bischof; Jürgen Debus; Peter E Huber Journal: Radiat Oncol Date: 2010-02-26 Impact factor: 3.481
Authors: E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-06 Impact factor: 9.236
Authors: Falk Roeder; Felix Zwicker; Ladan Saleh-Ebrahimi; Carmen Timke; Christian Thieke; Marc Bischof; Juergen Debus; Peter E Huber Journal: Radiat Oncol Date: 2011-03-01 Impact factor: 3.481
Authors: Florian Sterzing; Eva M Stoiber; Simeon Nill; Harald Bauer; Peter Huber; Jürgen Debus; Marc W Münter Journal: Radiat Oncol Date: 2009-09-23 Impact factor: 3.481